Glucosa Physan

Glucosa Physan is a parenteral solution for injection that contains glucose monohydrate as its sole active ingredient. The product is supplied as an intravenous solution, with the specific concentration not disclosed in the available data. Classified as an excipient and solvent, Glucosa Physan is marketed in the European Union and is used to provide a readily available source of glucose for patients requiring intravenous carbohydrate supplementation.

Glucosa Physan is indicated for clinical situations where rapid intravenous glucose delivery is required to support metabolic needs.

- Treatment of acute hypoglycemia when oral glucose administration is not feasible. - Component of parenteral nutrition regimens to supply carbohydrate calories. - Energy supplementation during surgical procedures or anesthesia. - Support for patients with prolonged fasting or inability to ingest food. - Maintenance of blood glucose levels in critically ill patients receiving intensive care. - Adjunctive therapy for patients undergoing dialysis who require glucose supplementation.

Glucosa Physan may be associated with a range of adverse reactions, most of which are related to its intravenous administration and the metabolic effects of glucose.

Common: - Transient hyperglycemia or elevated blood glucose levels. - Local irritation or pain at the injection site. - Mild electrolyte shifts, particularly sodium or potassium changes. - Nausea or mild gastrointestinal discomfort. - Temporary increase in serum osmolality. - Mild headache associated with rapid glucose rise.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic or anaphylactic reactions to excipients. - Volume overload or pulmonary edema in patients receiving large volumes. - Hypotension due to rapid infusion of large volumes. - Metabolic acidosis in patients with impaired glucose utilization. - Severe hyperglycemia leading to osmotic diuresis.

When using Glucosa Physan, clinicians should observe specific precautions to minimize risks associated with intravenous glucose administration and fluid loading.

- Verify patient’s blood glucose level before and during infusion. - Adjust infusion rate in patients with diabetes or impaired glucose tolerance. - Monitor electrolyte balance, especially sodium and potassium, during therapy. - Assess fluid status to avoid volume overload in heart‑failure or renal‑insufficient patients. - Use aseptic technique to prevent catheter‑related infections. - Consider contraindications such as known hypersensitivity to formulation components. - Document infusion volume and rate in the patient’s medical record for ongoing monitoring.

Glucosa Physan can interact with other agents administered intravenously, influencing glucose homeostasis or fluid balance.

Avoid: - Concurrent administration of high‑dose insulin without appropriate glucose monitoring. - Co‑infusion of hyperosmolar solutions that may exacerbate hyperglycemia. - Simultaneous infusion of calcium‑containing solutions, which may precipitate with glucose formulations.

Use with caution: - Diuretics that alter electrolyte levels, requiring close monitoring. - Vasopressors that may affect peripheral perfusion during infusion. - Total parenteral nutrition regimens, to avoid excessive carbohydrate load. - Renal replacement therapies, as glucose may be cleared variably. - Beta‑blockers, as they may mask symptoms of hypoglycemia during glucose infusion. - Anticoagulants, because rapid glucose infusion can affect coagulation parameters.